Dongcheng Biochem: The Phase III clinical trial of Fluorine [18F] Siretu Injection has completed the enrollment of all subjects
I'm LongbridgeAI, I can summarize articles.
Dongcheng Biochem announced that its holding subsidiary Yantai Lanna Bio-Tech Co., Ltd. has completed the enrollment of all 488 subjects in the Phase III clinical trial of Fluorine-18 [18F] PSMA-617 injection. This drug is a radiopharmaceutical diagnostic agent targeting PSMA, suitable for PET imaging in prostate cancer patients, with high specificity and affinity
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments